Metastatic renal cell carcinoma to the brain: optimizing patient selection for gamma knife radiosurgery

Stenman, Maria; Benmakhlouf, Hamza; Wersäll, Peter; Johnstone, Philippa; Hatiboğlu, Mustafa Aziz; Mayer-da-Silva, J; Harmenberg, Ulrika; Lindskog, Magnus; Sinclair, Georges

doi:10.1007/s00701-020-04537-w

Cited by 4 publications

(1 citation statement)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, the most recent study by Stenman et al in 2021 evaluated 43 patients with 194 targets that were irradiated with 88% of the cohort also receiving targeted therapies. This cohort was treated with single fraction gamma knife radiosurgery (sf-GKRS) after a median time of 8.5 months from metastatic renal cell carcinoma diagnosis and subsequent to sf-GKRS had a median overall survival of 15.7 months; reflecting a cumulative median overall survival of 24.2 months (86). Although the study did not show targeted agents to be associated with improved survival, when compared to historical data, a median overall survival at 24.2 months is an improvement in overall survival and supports the existence of synergy between targeted therapies and SRS.…”

Section: Renal Cell Carcinomamentioning

confidence: 99%

Improving Brain Metastases Outcomes Through Therapeutic Synergy Between Stereotactic Radiosurgery and Targeted Cancer Therapies

et al. 2022

View full text Add to dashboard Cite

Brain metastases are the most common form of brain cancer. Increasing knowledge of primary tumor biology, actionable molecular targets and continued improvements in systemic and radiotherapy regimens have helped improve survival but necessitate multidisciplinary collaboration between neurosurgical, medical and radiation oncologists. In this review, we will discuss the advances of targeted therapies to date and discuss findings of studies investigating the synergy between these therapies and stereotactic radiosurgery for non-small cell lung cancer, breast cancer, melanoma, and renal cell carcinoma brain metastases.

show abstract

Section: Renal Cell Carcinomamentioning

confidence: 99%

Improving Brain Metastases Outcomes Through Therapeutic Synergy Between Stereotactic Radiosurgery and Targeted Cancer Therapies

et al. 2022

View full text Add to dashboard Cite

show abstract

The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma

Ali¹,

Mooi²,

Lawrentschuk³

et al. 2022

European Urology

View full text Add to dashboard Cite

VEGFR-TKI treatment for radiation-induced brain injury after gamma knife radiosurgery for brain metastases from renal cell carcinomas

Noda

Akabane

Kawashima

et al. 2022

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

Objective Antiangiogenic vascular endothelial growth factor receptor tyrosine kinase inhibitors play an essential role in systemic therapy for renal cell carcinoma. Given the anti-edematous effect of bevacizumab, an antiangiogenic antibody targeting vascular endothelial growth factor, vascular endothelial growth factor receptor tyrosine kinase inhibitors should exert therapeutic effects on radiation-induced brain injury after stereotactic radiosurgery. This preliminary study aimed to investigate the therapeutic effect of vascular endothelial growth factor receptor tyrosine kinase inhibitor against radiation-induced brain injury. Methods Magnetic resonance images for six patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors who were diagnosed with radiation-induced brain injury following gamma knife radiosurgery were retrospectively reviewed. Results The median brain edema volume and tumour mass volume in the pre-tyrosine kinase inhibitor period were 57.6 mL (range: 39.4–188.2) and 3.2 mL (range: 1.0–4.6), respectively. Axitinib, pazopanib (followed by cabozantinib) and sunitinib were administered in four, one and one cases, respectively. The median brain edema volume and tumour mass volume in the post-tyrosine kinase inhibitor period were 4.8 mL (range: 1.5–27.8) and 1.6 mL (range: 0.4–3.6), respectively. The median rates of reduction in brain edema volume and tumour mass volume were 90.8% (range: 51.9–97.6%) and 57.2% (range: 20.0–68.6%), respectively. The post-tyrosine kinase inhibitor values for brain edema volume (P = 0.027) and tumour mass volume (P = 0.008) were significantly lower than the pre-tyrosine kinase inhibitor values. Changes in volume were correlated with tyrosine kinase inhibitor use. Conclusion This study is the first to demonstrate the therapeutic effects of vascular endothelial growth factor receptor tyrosine kinase inhibitors on radiation-induced brain injury in patients with brain metastases from renal cell carcinoma treated via gamma knife radiosurgery.

show abstract

Metastatic renal cell carcinoma to the brain: optimizing patient selection for gamma knife radiosurgery

Cited by 4 publications

References 62 publications

Improving Brain Metastases Outcomes Through Therapeutic Synergy Between Stereotactic Radiosurgery and Targeted Cancer Therapies

Improving Brain Metastases Outcomes Through Therapeutic Synergy Between Stereotactic Radiosurgery and Targeted Cancer Therapies

The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma

VEGFR-TKI treatment for radiation-induced brain injury after gamma knife radiosurgery for brain metastases from renal cell carcinomas

Contact Info

Product

Resources

About